Health
Dexamethasone use could reduce immune checkpoint inhibitor efficacy in glioblastoma patients – News-Medical.Net
Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral…
Reviewed by Emily Henderson, B.Sc.Nov 25 2020
Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival.
Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research
Author: David A. Reardon, MD, clinical director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute in…
-
General17 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Business17 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General19 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General20 hours agoAlbanese beats drum on economy as trade clouds gather